Skip to main content
Midas Edge

TELA Bio Inc

For the period ended Dec 31, 2023. Filed Mar 22, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 22, 2024

TELA$0.80-7.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · other · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Common stock · ​ · paid‑in · ​ · comprehensive · ​ · Accumulated · ​ · ​ · ​
​ · Shares · Amount · capital · income (loss) · deficit · Total
Balance at January 1, 2021​14,437,107​$14​$245,736​$(71)​$(196,653)​$49,026
Vesting of common stock previously subject to repurchase​153​—​1​—​—​​1
Vesting of share-based awards and exercise of stock options​89,154​1​546​—​—​​547
Issuance of common stock under the employee stock purchase plan​3,163​​—​​38​​—​​—​​38
Foreign currency translation adjustment​—​​—​​—​​19​​—​​19
Stock‑based compensation expense​—​—​3,661​—​—​3,661
Reclassification of liability-classified stock-based compensation awards​—​​—​​82​​—​​—​82
Net loss​—​—​—​—​(33,276)​(33,276)
Balance at December 31, 202114,529,577​​15​​250,064​​(52)​​(229,929)​​20,098
Vesting of common stock previously subject to repurchase29​—​—​—​—​—
Vesting of share-based awards and exercise of stock options44,346​—​19​—​—​19
Issuance of common stock under the employee stock purchase plan​4,523​—​50​—​—​50
Shares withheld for employee taxes​(13,448)​​—​​(157)​​—​​—​​(157)
Foreign currency translation adjustment—​​—​​—​​202​​—​202
Stock‑based compensation expense—​—​3,989​—​—​3,989
Sale of common stock, net of underwriting discounts, commissions and offering costs​4,600,000​​4​​34,396​​—​​—​​34,400
Net loss—​—​—​—​(44,296)​(44,296)
Balance at December 31, 202219,165,027​​19​​288,361​​150​​(274,225)​​14,305
Vesting of share-based awards and exercise of stock options126,987​—​127​—​—​127
Issuance of common stock under the employee stock purchase plan​10,602​​—​​88​​—​​—​​88
Shares withheld for employee taxes​(27,131)​​—​​(289)​​—​​—​​(289)
Foreign currency translation adjustment—​—​—​(59)​—​(59)
Stock‑based compensation expense​—​​—​​5,032​​—​​—​​5,032
Sale of common stock, net of underwriting discounts, commissions and offering costs​5,219,190​​5​​46,336​​—​​—​​46,341
Net loss—​—​—​—​(46,664)​(46,664)
Balance at December 31, 202324,494,675​$24​$339,655​$91​$(320,889)​$18,881
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.